Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by EuroLand Corporate. 

In a study entitled "L’imagerie cellulaire à la loupe", EuroLand Corporate recommends Mauna Kea shares to Buy, with a target price of €0.71, representing an increase of +56% compared with the share's closing price on January 31, 2024 (€0.456). 

This new study adds to the consensus of financial analysts who already covers the stock alongside Portzamparc and Gilbert Dupont.